Furthermore, they found that miRNA-106a directly targeted RARß and could regulate NIS and TSHR expression and RAI uptake in thyroid cancers, suggesting miRNA-106a as a new diagnostic and therapeutic target. Here, SLC5A5 is linked to thyroid gland carcinoma.